Filter posts

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

Insights in to the molecular and genetic basis of disease are driving new product and …

Multiple Assets Diversify the Deal

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery …

Public Exits and Virtual Biotechs - Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the …

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and …

BIO Investor Forum Company Snapshot: Protagonist Therapeutics

In our final Investor Forum Company Snapshot, we’ve profiled one of the Discovery Companies who …

BIO Investor Forum Company Snapshot: Immune Design

In the third installment of the Investor Forum Company Snapshots, hear from Immune Design Corp. …

Perspective on Market Valuation for Biotech Drug Developers

Of the 300 publicly traded U.S. biotechs, 219 (73%) are developing drugs. The other 27% …

Technology Transfer Symposium in San Francisco

In the midst of turbulent economic times, and at a moment when the U.S. is …

BIO Investor Forum Company Snapshot: Syndax Pharmaceuticals

Next up in our Company Snapshot segment for the BIO Investor Forum is another presenting …

BIO Investor Forum Company Snapshot: GlobeImmune, Inc.

The BIO Investor Forum will be here before we know it, and we wanted to …